Enhanced fungal specificity and in vivo therapeutic efficacy of a C-22-modified FK520 analog against C. neoformans
IMPORTANCE: Fungal infections cause significant morbidity and mortality globally. The therapeutic armamentarium against these infections is limited, and the development of antifungal drugs has been hindered by the evolutionary conservation between fungi and the human host. With rising resistance to the current antifungal arsenal and an increasing at-risk population, there is an urgent need for the development of new antifungal compounds. The FK520 analogs described in this study display potent antifungal activity as a novel class of antifungals centered on modifying an existing orally active FDA-approved therapy. This research advances the development of much-needed newer antifungal treatment options with novel mechanisms of action.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
mBio - 14(2023), 5 vom: 31. Okt., Seite e0181023 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rivera, Angela [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antifungal Agents |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 25.12.2023 published: Print-Electronic UpdateOf: bioRxiv. 2023 Jul 11;:. - PMID 37333270 Citation Status MEDLINE |
|---|
| doi: |
10.1128/mbio.01810-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362341532 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362341532 | ||
| 003 | DE-627 | ||
| 005 | 20231227140900.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/mbio.01810-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1238.xml |
| 035 | |a (DE-627)NLM362341532 | ||
| 035 | |a (NLM)37737622 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rivera, Angela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhanced fungal specificity and in vivo therapeutic efficacy of a C-22-modified FK520 analog against C. neoformans |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 25.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: bioRxiv. 2023 Jul 11;:. - PMID 37333270 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a IMPORTANCE: Fungal infections cause significant morbidity and mortality globally. The therapeutic armamentarium against these infections is limited, and the development of antifungal drugs has been hindered by the evolutionary conservation between fungi and the human host. With rising resistance to the current antifungal arsenal and an increasing at-risk population, there is an urgent need for the development of new antifungal compounds. The FK520 analogs described in this study display potent antifungal activity as a novel class of antifungals centered on modifying an existing orally active FDA-approved therapy. This research advances the development of much-needed newer antifungal treatment options with novel mechanisms of action | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a antifungal agents | |
| 650 | 4 | |a mycology | |
| 650 | 4 | |a natural antimicrobial products | |
| 650 | 4 | |a pharmacology | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 700 | 1 | |a Young Lim, Won |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Eunchong |e verfasserin |4 aut | |
| 700 | 1 | |a Dome, Patrick A |e verfasserin |4 aut | |
| 700 | 1 | |a Hoy, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Spasojevic, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Averette, Anna Floyd |e verfasserin |4 aut | |
| 700 | 1 | |a Pina-Oviedo, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Juvvadi, Praveen R |e verfasserin |4 aut | |
| 700 | 1 | |a Steinbach, William J |e verfasserin |4 aut | |
| 700 | 1 | |a Ciofani, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Jiyong |e verfasserin |4 aut | |
| 700 | 1 | |a Heitman, Joseph |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t mBio |d 2010 |g 14(2023), 5 vom: 31. Okt., Seite e0181023 |w (DE-627)NLM200128191 |x 2150-7511 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:5 |g day:31 |g month:10 |g pages:e0181023 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/mbio.01810-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 5 |b 31 |c 10 |h e0181023 | ||